GlassScriptPhysician profile
Teresa Smith
NPI 1326411679
$7,153.42
in general payments reported to CMS, 2019-2025
30 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $969 · 2022: $953 · 2023: $1,561 · 2024: $1,766 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,231.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,414.94 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,018.16 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $781.81 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $460.42 | 2024-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $413.42 | 2022-2024 | Ingrezza |
| Novo Nordisk INC | $363.54 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Astellas Pharma US INC | $356.17 | 2023-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $300.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $249.72 | 2024-2025 | Rexulti |
| Acadia Pharmaceuticals INC | $237.22 | 2022-2023 | Nuplazid |
| Genzyme Corporation | $234.66 | 2022-2024 | |
| Amgen INC. | $165.20 | 2021-2023 | Repatha |
| Optinose US, INC. | $126.67 | 2022 | |
| Avanir Pharmaceuticals, INC. | $125.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $125.00 | 2023 | Xarelto |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $125.00 | 2025 | Rezdiffra |
| Kyowa Kirin, INC. | $110.41 | 2025 | |
| Access Vascular INC | $86.60 | 2022 | |
| Lilly USA, LLC | $86.11 | 2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $67.74 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.78 | 2023-2025 | Jardiance |
| Verona Pharma, INC. | $38.97 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $36.57 | 2025 | Gardasil 9, Capvaxive, Rotateq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.29 | 2023 | Xifaxan |
| Philips North America LLC | $33.51 | 2024 | (Ck7) Extended Holter |
| Dexcom, INC. | $31.35 | 2024-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $27.32 | 2023 | Gvoke Hypopen |
| International Rehabilitative Sciences, INC | $14.53 | 2025 | Rs-4i Plus With Intersperse |
| Esperion Therapeutics, INC. | $14.35 | 2025 | Nexletol |
| Seqirus USA INC | $13.64 | 2025 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.